Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $79,427.88 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider James William Burns sold 2,932 shares of the company’s stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider owned 31,718 shares of the company’s stock, valued at approximately $859,240.62. This trade represents a 8.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Agios Pharmaceuticals Trading Down 0.1%

AGIO opened at $27.18 on Monday. The business’s 50 day moving average is $32.20 and its 200-day moving average is $35.97. The stock has a market cap of $1.58 billion, a PE ratio of -3.88 and a beta of 0.89. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($1.93) by $0.15. The firm had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The firm’s revenue was up 43.3% compared to the same quarter last year. During the same period last year, the firm earned $16.22 EPS. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AGIO shares. HC Wainwright increased their target price on shares of Agios Pharmaceuticals from $48.00 to $62.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. Zacks Research raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. Leerink Partnrs upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 20th. Leerink Partners boosted their target price on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.89.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AGIO. Wellington Management Group LLP lifted its position in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after acquiring an additional 2,049,287 shares during the last quarter. TCG Crossover Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after purchasing an additional 733,038 shares during the last quarter. SCS Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 1st quarter valued at $17,905,000. Balyasny Asset Management L.P. purchased a new position in Agios Pharmaceuticals in the 3rd quarter worth about $19,889,000. Finally, Adage Capital Partners GP L.L.C. raised its holdings in Agios Pharmaceuticals by 145.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company’s stock worth $21,770,000 after buying an additional 440,000 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.